Biocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Stock Looks Expensive, Wait for Pullbacks
BioCryst Stock Is Another Player in the WallStreetBets Shorted Rallies
What Sarepta Therapeutics’ Valuation Trend Indicates
Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter compared to a net loss of $63.05 million in Q2 2017.